Cargando…

COVID-19 in multiple-myeloma patients: cellular and humoral immunity against SARS-CoV-2 in a short- and long-term view

ABSTRACT: Multiple myeloma patients are often treated with immunomodulatory drugs, proteasome inhibitors, or monoclonal antibodies until disease progression. Continuous therapy in combination with the underlying disease frequently results in severe humoral and cellular immunodeficiency, which often...

Descripción completa

Detalles Bibliográficos
Autores principales:	von Metzler, Ivana, Campe, Julia, Huenecke, Sabine, Raab, Marc S., Goldschmidt, Hartmut, Schubert, Ralf, Rabenau, Holger F., Ciesek, Sandra, Serve, Hubert, Ullrich, Evelyn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520766/ https://www.ncbi.nlm.nih.gov/pubmed/34657968 http://dx.doi.org/10.1007/s00109-021-02114-x

Ejemplares similares

Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma
por: Enssle, Julius C., et al.
Publicado: (2022)

Portraying Immunity to Sars-Cov-2 after mRNA-Vaccination in Patients with Multiple Myeloma
por: Enssle, Julius Christoph, et al.
Publicado: (2022)

PB2070: IMMUNE RESPONSES AFTER SARS-COV-2 MRNA-VACCINATION AND INFECTION AT SINGLE CELL RESOLUTION IN PATIENTS WITH MULTIPLE MYELOMA
por: Enssle, Julius C., et al.
Publicado: (2023)

Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma
por: Enßle, Julius C., et al.
Publicado: (2022)

Enhancing the Activation and Releasing the Brakes: A Double Hit Strategy to Improve NK Cell Cytotoxicity Against Multiple Myeloma
por: Tognarelli, Sara, et al.
Publicado: (2018)

CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma
por: Bexte, Tobias, et al.
Publicado: (2022)

Novel immunotherapies in multiple myeloma – chances and challenges
por: Rasche, Leo, et al.
Publicado: (2021)

Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study
por: Kohmer, Niko, et al.
Publicado: (2023)

T Helper Cell Lineage-Defining Transcription Factors: Potent Targets for Specific GVHD Therapy?
por: Campe, Julia, et al.
Publicado: (2022)

Riding the Omicron BA.5 Wave: Improved Humoral Response after Vaccination with Bivalent Omicron BA.4-5-Adapted mRNA SARS-CoV-2 Vaccine in Chronic Hemodialysis Patients
por: Ovcar, Eugen, et al.
Publicado: (2023)

SARS-CoV-2 Vaccination in Kidney Transplant Recipients—Stratified Analysis of the Humoral Immune Response
por: Lammert, Alexander, et al.
Publicado: (2022)

Therapeutic Advances Propelled by Deciphering Tumor Biology and Immunology—Highlights of the 8th Heidelberg Myeloma Workshop
por: Lutz, Raphael, et al.
Publicado: (2021)

Thirty years of CMV seroprevalence—a longitudinal analysis in a German university hospital
por: Hoehl, Sebastian, et al.
Publicado: (2020)

Utility of Different Surrogate Enzyme-Linked Immunosorbent Assays (sELISAs) for Detection of SARS-CoV-2 Neutralizing Antibodies
por: Kohmer, Niko, et al.
Publicado: (2021)

Suitability of Different Diagnostic Platforms for Virological Testing of Blood Samples from Cornea Donors
por: Kohmer, Niko, et al.
Publicado: (2022)

Clinical performance of different SARS‐CoV‐2 IgG antibody tests
por: Kohmer, Niko, et al.
Publicado: (2020)

Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays
por: Kohmer, Niko, et al.
Publicado: (2020)

Mitochondrial apoptosis: facilitator of NK cell-mediated immunotherapy
por: Ullrich, Evelyn, et al.
Publicado: (2022)

Impact of Moderna mRNA-1273 Booster Vaccine on Fully Vaccinated High-Risk Chronic Dialysis Patients after Loss of Humoral Response
por: Patyna, Sammy, et al.
Publicado: (2022)

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
por: Gay, Francesca, et al.
Publicado: (2018)

Comparative analysis of point-of-care, high-throughput and laboratory-developed SARS-CoV-2 nucleic acid amplification tests (NATs)
por: Kohmer, Niko, et al.
Publicado: (2021)

Identification of the Cysteine Protease Legumain as a Potential Chronic Hypoxia-Specific Multiple Myeloma Target Gene
por: Clees, Ada-Sophia, et al.
Publicado: (2022)

Can (18)F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma?
por: Sachpekidis, Christos, et al.
Publicado: (2020)

Low But Recoverable Markers of Humoral Immune Response to BNT162b2 in Elderly LTCF Residents Five to Seven Months After Two-Dose Vaccination
por: Delbrück, Marla, et al.
Publicado: (2022)

Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma
por: Sachpekidis, Christos, et al.
Publicado: (2019)

A systematic classification of death causes in multiple myeloma
por: Mai, Elias K., et al.
Publicado: (2018)

Evaluation of stability and inactivation methods of SARS-CoV-2 in context of laboratory settings
por: Widera, Marek, et al.
Publicado: (2021)

Cellular Immune Composition in Multiple Myeloma Patients Associated with Variable Humoral Responses to Sars-Cov-2 Vaccination
por: Kogan Zajdman, Ariel, et al.
Publicado: (2022)

Pre-emptive Allogeneic Hematopoietic Stem Cell Transplantation in Ataxia Telangiectasia
por: Bakhtiar, Shahrzad, et al.
Publicado: (2018)

The prognostic significance of [(18)F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs)
por: Sachpekidis, Christos, et al.
Publicado: (2021)

Navigating the treatment landscape in multiple myeloma: which combinations to use and when?
por: Goldschmidt, Hartmut, et al.
Publicado: (2018)

Analysis of long‐term survival in multiple myeloma after first‐line autologous stem cell transplantation: impact of clinical risk factors and sustained response
por: Lehners, Nicola, et al.
Publicado: (2017)

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2021)

Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma
por: John, Lukas, et al.
Publicado: (2023)

Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1
por: Wagner, Verena, et al.
Publicado: (2014)

Attitudes of influenza‐vaccinated health care workers toward masks to prevent nosocomial transmission of influenza
por: Brandt, Christian, et al.
Publicado: (2010)

Cellular and Humoral Immunity against Different SARS-CoV-2 Variants Is Detectable but Reduced in Vaccinated Kidney Transplant Patients
por: Thümmler, Laura, et al.
Publicado: (2022)

SARS‐CoV‐2‐specific T cells are generated in less than half of allogeneic HSCT recipients failing to seroconvert after COVID‐19 vaccination
por: Jarisch, Andrea, et al.
Publicado: (2022)

Respiratory viruses in medicolegal autopsies during the winter season 2021/2022: observations after reduction of coronavirus disease-19 (COVID-19) pandemic restrictions
por: Plenzig, S., et al.
Publicado: (2023)

Playing with Expectations: A Contextual View of Humor Development
por: Airenti, Gabriella
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dsvj6n87007mcj77ege0rb87ci